<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7392210\results\search\disease\results.xml">
  <result pre="- including this research content - immediately available in PubMed" exact="Central" post="and other publicly funded repositories, such as the WHO"/>
  <result pre="COVID-19 SARS-CoV-2 Coronavirus Drugs Vaccines Clinical trials Abbreviations COVID-19, Coronavirus" exact="Disease" post="2019 SARS-CoV-2, Severe Acute Respiratory Syndrome Coronavirus 2 WHO,"/>
  <result pre="Drugs Vaccines Clinical trials Abbreviations COVID-19, Coronavirus Disease 2019 SARS-CoV-2," exact="Severe" post="Acute Respiratory Syndrome Coronavirus 2 WHO, World Health Organization"/>
  <result pre="Vaccines Clinical trials Abbreviations COVID-19, Coronavirus Disease 2019 SARS-CoV-2, Severe" exact="Acute" post="Respiratory Syndrome Coronavirus 2 WHO, World Health Organization ICTV,"/>
  <result pre="Clinical trials Abbreviations COVID-19, Coronavirus Disease 2019 SARS-CoV-2, Severe Acute" exact="Respiratory" post="Syndrome Coronavirus 2 WHO, World Health Organization ICTV, International"/>
  <result pre="trials Abbreviations COVID-19, Coronavirus Disease 2019 SARS-CoV-2, Severe Acute Respiratory" exact="Syndrome" post="Coronavirus 2 WHO, World Health Organization ICTV, International Committee"/>
  <result pre="Health Organization ICTV, International Committee on Taxonomy of Viruses ARDS," exact="acute" post="respiratory distress syndrome SARS, Severe Acute Respiratory Syndrome MERS,"/>
  <result pre="Organization ICTV, International Committee on Taxonomy of Viruses ARDS, acute" exact="respiratory" post="distress syndrome SARS, Severe Acute Respiratory Syndrome MERS, Middle"/>
  <result pre="International Committee on Taxonomy of Viruses ARDS, acute respiratory distress" exact="syndrome" post="SARS, Severe Acute Respiratory Syndrome MERS, Middle East Respiratory"/>
  <result pre="on Taxonomy of Viruses ARDS, acute respiratory distress syndrome SARS," exact="Severe" post="Acute Respiratory Syndrome MERS, Middle East Respiratory Syndrome R0,"/>
  <result pre="Taxonomy of Viruses ARDS, acute respiratory distress syndrome SARS, Severe" exact="Acute" post="Respiratory Syndrome MERS, Middle East Respiratory Syndrome R0, reproductive"/>
  <result pre="of Viruses ARDS, acute respiratory distress syndrome SARS, Severe Acute" exact="Respiratory" post="Syndrome MERS, Middle East Respiratory Syndrome R0, reproductive ratio"/>
  <result pre="Viruses ARDS, acute respiratory distress syndrome SARS, Severe Acute Respiratory" exact="Syndrome" post="MERS, Middle East Respiratory Syndrome R0, reproductive ratio SI,"/>
  <result pre="distress syndrome SARS, Severe Acute Respiratory Syndrome MERS, Middle East" exact="Respiratory" post="Syndrome R0, reproductive ratio SI, Serial Interval PPE, Personal"/>
  <result pre="syndrome SARS, Severe Acute Respiratory Syndrome MERS, Middle East Respiratory" exact="Syndrome" post="R0, reproductive ratio SI, Serial Interval PPE, Personal Protective"/>
  <result pre="angiotensin I converting enzyme 2 RAS, Renin-Angiotensin System ATII, alveolar" exact="Type II" post="cells RdRp, RNA-dependent RNA polymerase TMPRSS2, type-2 transmembrane serine"/>
  <result pre="polymerase TMPRSS2, type-2 transmembrane serine protease IL-6, interleukin 6 TNFÎ±," exact="tumor" post="necrosis factor Î± MCP-1, monocyte chemoattractant protein-1 NK, natural"/>
  <result pre="protease IL-6, interleukin 6 TNFÎ±, tumor necrosis factor Î± MCP-1," exact="monocyte" post="chemoattractant protein-1 NK, natural killer cells S protein, viral"/>
  <result pre="MCP-1, monocyte chemoattractant protein-1 NK, natural killer cells S protein," exact="viral" post="spike protein aAPC, artificial antigen-presenting cells CP, Convalescent Plasma"/>
  <result pre="7, 2020, scientists had isolated a novel coronavirus from the" exact="lower" post="respiratory tract samples of patients who were admitted to"/>
  <result pre="2020, scientists had isolated a novel coronavirus from the lower" exact="respiratory" post="tract samples of patients who were admitted to a"/>
  <result pre="in Wuhan [4]. This pathogen was later termed as severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) by the International Committee"/>
  <result pre="Wuhan [4]. This pathogen was later termed as severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) by the International Committee on"/>
  <result pre="[4]. This pathogen was later termed as severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) by the International Committee on Taxonomy"/>
  <result pre="Taxonomy of Viruses (ICTV) [5]. The WHO declared this novel" exact="viral" post="disease a Public Health Emergency of International Concern on"/>
  <result pre="of Viruses (ICTV) [5]. The WHO declared this novel viral" exact="disease" post="a Public Health Emergency of International Concern on 30"/>
  <result pre="30 January 2020, and subsequently termed it as COVID-19 (Coronavirus" exact="Disease" post="2019) [6] on February 11, 2020. The first fatality"/>
  <result pre="the Chinese New Year fuelled the rapid spread of the" exact="disease" post="to all parts of the globe, which led to"/>
  <result pre="of beta-coronaviruses found in humans cause mild illnesses of the" exact="upper" post="respiratory tract such as common cold (also caused by"/>
  <result pre="beta-coronaviruses found in humans cause mild illnesses of the upper" exact="respiratory" post="tract such as common cold (also caused by rhinoviruses)."/>
  <result pre="as common cold (also caused by rhinoviruses). Two other kinds," exact="Severe" post="Acute Respiratory Syndrome Coronavirus (SARS-CoV) and Middle East Respiratory"/>
  <result pre="common cold (also caused by rhinoviruses). Two other kinds, Severe" exact="Acute" post="Respiratory Syndrome Coronavirus (SARS-CoV) and Middle East Respiratory Syndrome"/>
  <result pre="cold (also caused by rhinoviruses). Two other kinds, Severe Acute" exact="Respiratory" post="Syndrome Coronavirus (SARS-CoV) and Middle East Respiratory Syndrome Coronavirus"/>
  <result pre="(also caused by rhinoviruses). Two other kinds, Severe Acute Respiratory" exact="Syndrome" post="Coronavirus (SARS-CoV) and Middle East Respiratory Syndrome Coronavirus (MERS-CoV),"/>
  <result pre="kinds, Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) and Middle East" exact="Respiratory" post="Syndrome Coronavirus (MERS-CoV), are considerably more dangerous (mortality rates"/>
  <result pre="Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) and Middle East Respiratory" exact="Syndrome" post="Coronavirus (MERS-CoV), are considerably more dangerous (mortality rates of"/>
  <result pre="bat (primary host) from where it mutated to infect the" exact="intermediate" post="host- Civet cats (a nocturnal mammal sold for meat"/>
  <result pre="it mutated to infect the intermediate host- Civet cats (a" exact="nocturnal" post="mammal sold for meat in China) and subsequently infected"/>
  <result pre="emerged in the Middle East with Dromedary Camel as the" exact="intermediate" post="host from which it mutated enough to affect humans,"/>
  <result pre="[4], [14] and made its way to humans via an" exact="intermediate" post="animal host, the pangolin [11], [15], a nocturnal mammal"/>
  <result pre="via an intermediate animal host, the pangolin [11], [15], a" exact="nocturnal" post="mammal that is highly trafficked around the world for"/>
  <result pre="2 . Fig. 1 Diagrammatic representation of the structure of" exact="Severe" post="Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). The figure represents"/>
  <result pre=". Fig. 1 Diagrammatic representation of the structure of Severe" exact="Acute" post="Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). The figure represents the"/>
  <result pre="Fig. 1 Diagrammatic representation of the structure of Severe Acute" exact="Respiratory" post="Syndrome Coronavirus 2 (SARS-CoV-2). The figure represents the viral"/>
  <result pre="1 Diagrammatic representation of the structure of Severe Acute Respiratory" exact="Syndrome" post="Coronavirus 2 (SARS-CoV-2). The figure represents the viral structure"/>
  <result pre="Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). The figure represents the" exact="viral" post="structure of SARS-CoV-2. The spike glycoprotein (S protein) confers"/>
  <result pre="Up to 80% of cases are asymptomatic or have mild" exact="disease" post="[19]. In some patients, underlying co-morbidities can further exacerbate"/>
  <result pre="co-morbidities can further exacerbate the diseased condition, leading to pneumonia," exact="acute" post="respiratory distress syndrome (ARDS), and multi-organ dysfunction by the"/>
  <result pre="can further exacerbate the diseased condition, leading to pneumonia, acute" exact="respiratory" post="distress syndrome (ARDS), and multi-organ dysfunction by the end"/>
  <result pre="exacerbate the diseased condition, leading to pneumonia, acute respiratory distress" exact="syndrome" post="(ARDS), and multi-organ dysfunction by the end of the"/>
  <result pre="the first week, eventually proving fatal. 4 Transmission Inhalation of" exact="respiratory" post="droplets generated by symptomatic patientsâ€™ cough and sneeze is"/>
  <result pre="proving fatal. 4 Transmission Inhalation of respiratory droplets generated by" exact="symptomatic" post="patientsâ€™ cough and sneeze is the main mode of"/>
  <result pre="of the virus to seemingly healthy individuals who touch their" exact="mucosa" post="(mouth, nose) and conjunctiva (eyes) without proper sanitization. Asymptomatic"/>
  <result pre="30Â min [23], [24]. 6 Epidemiology Despite being relatively more" exact="benign" post="than its two ancestors, SARS-CoV-2 has crossed the 15"/>
  <result pre="(SI) of 5â€&quot;7.5Â days [26], which are indicative of an" exact="infectious disease" post="that has the potential of rapidly turning into a"/>
  <result pre="of 5â€&quot;7.5Â days [26], which are indicative of an infectious" exact="disease" post="that has the potential of rapidly turning into a"/>
  <result pre="into a pandemic. Sanche et al. recently suggested that the" exact="disease" post="had a median R0 of 5.7 (95% CI of"/>
  <result pre="R0 of SARS was 2 and 1.3 for the 2009" exact="H1N1 Influenza" post="[26].The mortality rate for COVID-19 ranges between 2 and"/>
  <result pre="leading cause of death [4]. 7 Current management In the" exact="absence of" post="any established pharmacological agents, supportive care remains the cornerstone"/>
  <result pre="(PPE) to reduce the risk of interpersonal transmission. The conspicuous" exact="absence of" post="any proven interventions for COVID-19 [28], coupled with the"/>
  <result pre="effective therapeutic agents for the prevention and treatment of the" exact="disease" post="by providing potential drug targets. This review outlines the"/>
  <result pre="SARS-CoV-2 enters human cells through its Spike (S) protein- a" exact="type I" post="surface glycoprotein, and binds to the angiotensin I converting"/>
  <result pre="I converting enzyme 2 (ACE2) receptor [29]. ACE2 is a" exact="type 1" post="transmembrane aminopeptidase expressed in the heart and lungs. It"/>
  <result pre="ACE2 is a type 1 transmembrane aminopeptidase expressed in the" exact="heart" post="and lungs. It negatively regulates the Renin-Angiotensin System (RAS)"/>
  <result pre="and plays a significant role in neurohumoral regulation of the" exact="cardiovascular" post="system. When SARS-CoV-2 binds to ACE2, it alters the"/>
  <result pre="to ACE2, it alters the ACE2 signaling pathways, potentially causing" exact="acute" post="myocardial and lung injury [30], [31]. ACE2 receptors are"/>
  <result pre="distributed in the epithelia of the lung- especially the alveolar" exact="Type II" post="(ATII) cells. Once the virus binds to the receptor,"/>
  <result pre="blood circulation. Fig. 3 shows a schematic representation of the" exact="viral" post="replication of SARS-CoV-2 inside a host ATII cell. ACE2"/>
  <result pre="for a cytokine storm [2] and eventually lead to ARDS," exact="secondary" post="infections and multi-organ damage, resulting in death. Fig. 3"/>
  <result pre="a cytokine storm [2] and eventually lead to ARDS, secondary" exact="infections" post="and multi-organ damage, resulting in death. Fig. 3 Schematic"/>
  <result pre="in death. Fig. 3 Schematic representation of the entry of" exact="Severe" post="Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) into host cell,"/>
  <result pre="death. Fig. 3 Schematic representation of the entry of Severe" exact="Acute" post="Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) into host cell, its"/>
  <result pre="Fig. 3 Schematic representation of the entry of Severe Acute" exact="Respiratory" post="Syndrome Coronavirus 2 (SARS-CoV-2) into host cell, its viral"/>
  <result pre="3 Schematic representation of the entry of Severe Acute Respiratory" exact="Syndrome" post="Coronavirus 2 (SARS-CoV-2) into host cell, its viral lifecycle"/>
  <result pre="Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) into host cell, its" exact="viral" post="lifecycle and potential drug targets. The above-mentioned figure depicts"/>
  <result pre="lifecycle and potential drug targets. The above-mentioned figure depicts the" exact="viral" post="processing of SARS-CoV-2 within host cells. S protein has"/>
  <result pre="the human host cell, leading to the release of the" exact="viral" post="RNA into the host cell which triggers a cascade"/>
  <result pre="host cell which triggers a cascade that ultimately results in" exact="respiratory" post="infection. Select repurposed drugs and their target sites of"/>
  <result pre="schematic. ACE2: angiotensin-converting enzyme 2; S protein: spike protein; TMPRSS2:" exact="type 2" post="trans-membrane serine protease and IL-6: interleukin 6. 10 Pharmacological"/>
  <result pre="of first usage) Class &amp;amp; Type Rationale for Use Target" exact="Disease" post="Dosage in Current Trials Supportive Evidence Caveats References Remdesivir(2014)"/>
  <result pre="[34], [35], [36], [37] Lopinavir/Ritonavir (LPV/r)(2000) Antiviral; Protease inhibitors HIV" exact="type 1" post="aspartate protease inhibitor with inhibitory activity against SARS-CoV in-vitro."/>
  <result pre="both in vitro and human studies Current data suggest a" exact="limited" post="role in treatment of COVID-19. [45], [46], [47] Oseltamivir(1999)"/>
  <result pre="of COVID-19. [45], [46], [47] Oseltamivir(1999) Antiviral; Neuraminidase inhibitor Inhibits" exact="viral" post="replication. Influenza 75Â mg orally twice a day for"/>
  <result pre="polymerase inhibitor RNA-dependent RNA polymerase inhibitor. Also involved in blocking" exact="viral" post="replication. Influenza, arenavirus, filovirus 1600Â mg twice daily on"/>
  <result pre="COVID-19 [34], [52], [53] Ribavirin (1986) Antiviral; Nucleoside analogue Inhibits" exact="viral" post="RNA synthesis and mRNA capping. Syncytial virus, viral hemorrhagic"/>
  <result pre="analogue Inhibits viral RNA synthesis and mRNA capping. Syncytial virus," exact="viral" post="hemorrhagic fever, 400Â mg twice daily for 14Â days"/>
  <result pre="potential clinical benefit. [34], [50] Camostatmesylate (2006) Protease inhibitors Blocks" exact="viral" post="maturation and entry to cells. Inhibits TMPRSS2. Pancreatitis 2"/>
  <result pre="Also showed antiviral activity in an animal model for SARS-CoV" exact="infection" post="Limited data available. [57], [58] Hydroxychloroquine / chloroquine (HCQ/CQ)"/>
  <result pre="showed antiviral activity in an animal model for SARS-CoV infection" exact="Limited" post="data available. [57], [58] Hydroxychloroquine / chloroquine (HCQ/CQ) (1955/1934)"/>
  <result pre="available. [57], [58] Hydroxychloroquine / chloroquine (HCQ/CQ) (1955/1934) Antimalarial Block" exact="viral" post="entry into cells by inhibiting glycosylation of host receptors,"/>
  <result pre="inhibiting glycosylation of host receptors, proteolytic processing, and endosomal acidification." exact="Malaria" post="Chloroquine: 500Â mg twice daily for 10Â daysHydroxychloroquine: 400Â"/>
  <result pre="COVID-19.Concerns of cardiac arrhythmias [52], [59], [61] Tocilizumab (2005) Monoclonal" exact="Antibody" post="IL-6 inhibitor. May block cytokine storm in COVID-19 patients."/>
  <result pre="Antibody IL-6 inhibitor. May block cytokine storm in COVID-19 patients." exact="Rheumatoid arthritis" post="8Â mg/kg IV (up to a maximum of 800Â"/>
  <result pre="IL-6 inhibitor. May block cytokine storm in COVID-19 patients. Rheumatoid" exact="arthritis" post="8Â mg/kg IV (up to a maximum of 800Â"/>
  <result pre="interval of 12Â h(NCT04317092) No data on SARS or MERS." exact="Limited" post="data to support current use. [67] Methylpred-nisolone (1957) Corticosteroids"/>
  <result pre="Potent anti-inflammatory and antifibrotic properties; May prevent â€œcytokine stormâ€�; reduce" exact="pulmonary" post="and systemic inflammation in pneumonia. Arthritis, psoriasis, etc. 120Â"/>
  <result pre="and antifibrotic properties; May prevent â€œcytokine stormâ€�; reduce pulmonary and" exact="systemic" post="inflammation in pneumonia. Arthritis, psoriasis, etc. 120Â mg/day IV"/>
  <result pre="SARS-CoV-1 and MERS-CoV [35]. Because of its high selectivity for" exact="viral" post="polymerases, Remdesivir is less likely to cause toxicity in"/>
  <result pre="(ChiCTR2000029308), LPV/r failed to reduce overall mortality as well as" exact="viral" post="load [47]. Thus it is difficult to ascertain whether"/>
  <result pre="into its phosphoribosylated form (favipiravir-RTP) in cells, which then inhibits" exact="viral" post="RNA polymerase activity [53]. It has shown potential in-vitro"/>
  <result pre="cases [56]. 10.1.1.5 Ribavirin Ribavirin, a guanosine analog prescribed for" exact="viral" post="hemorrhagic fever and respiratory syncytial virus, inhibits viral RNA"/>
  <result pre="Ribavirin, a guanosine analog prescribed for viral hemorrhagic fever and" exact="respiratory" post="syncytial virus, inhibits viral RNA polymerase and mRNA capping."/>
  <result pre="prescribed for viral hemorrhagic fever and respiratory syncytial virus, inhibits" exact="viral" post="RNA polymerase and mRNA capping. It has no in-vitro"/>
  <result pre="in-vitro than antivirals like Remdesivir [34]. It is associated with" exact="hemolytic anemia" post="which could lead to exacerbation of cardiac disease in"/>
  <result pre="than antivirals like Remdesivir [34]. It is associated with hemolytic" exact="anemia" post="which could lead to exacerbation of cardiac disease in"/>
  <result pre="associated with hemolytic anemia which could lead to exacerbation of" exact="cardiac disease" post="in co-morbid patients. Further, it is also known to"/>
  <result pre="with hemolytic anemia which could lead to exacerbation of cardiac" exact="disease" post="in co-morbid patients. Further, it is also known to"/>
  <result pre="a protease inhibitor that is used for the treatment of" exact="chronic" post="pancreatitis. Camostat inhibits the host cell serine protease TMPRSS2"/>
  <result pre="the host cell serine protease TMPRSS2 [57], which primes the" exact="viral" post="S protein for entry into human cells. In mice,"/>
  <result pre="that in humans [58]. It also was found to block" exact="viral" post="maturation and entry of SARS-Cov-2 in vitro. Eight trials"/>
  <result pre="studies are currently underway around the world. There is very" exact="limited" post="data to advocate the use of HCQ/CQ as therapeutic"/>
  <result pre="patients in the HCQ plus Azithromycin group had significantly better" exact="viral" post="clearance [60]. However, six patients in the HCQ group"/>
  <result pre="There was also no reported evidence of a decrease in" exact="viral" post="load or improvement in other clinical outcomes. A recent"/>
  <result pre="inhibits IL-6 receptors and is used for the treatment of" exact="rheumatoid arthritis" post="and the â€œcytokine stormâ€� immune overresponse in cancer patients."/>
  <result pre="IL-6 receptors and is used for the treatment of rheumatoid" exact="arthritis" post="and the â€œcytokine stormâ€� immune overresponse in cancer patients."/>
  <result pre="of rheumatoid arthritis and the â€œcytokine stormâ€� immune overresponse in" exact="cancer" post="patients. IL-6 is implicated in immunologic response in patients"/>
  <result pre="implicated in immunologic response in patients with Cytokine-release syndromes (CRS)." exact="Elevated" post="levels of IL-6 have been associated with hyperinflammatory states"/>
  <result pre="potentially lead to increased rates of mortality [67]. Patients with" exact="thrombocytopenia" post="and neutropenia are at a greater risk of possible"/>
  <result pre="to increased rates of mortality [67]. Patients with thrombocytopenia and" exact="neutropenia" post="are at a greater risk of possible ADRs of"/>
  <result pre="[68]. The drug was also reported to be associated with" exact="lower" post="mortality in a cohort of mechanically ventilated COVID-19 patients"/>
  <result pre="clinical improvement or mortality [70]. 10.2.1.2 Sarilumab IL-6 Receptor-Inhibiting Monoclonal" exact="Antibody" post="that has been previously used in the treatment of"/>
  <result pre="Antibody that has been previously used in the treatment of" exact="Rheumatoid arthritis." post="It is currently being tested in more than fifteen"/>
  <result pre="trial showed that Sarilumab did not meet any of the" exact="primary" post="or secondary endpoints of the study and is thus"/>
  <result pre="that Sarilumab did not meet any of the primary or" exact="secondary" post="endpoints of the study and is thus ineffective in"/>
  <result pre="Ruxolitinib has been found to be effective against inflammatory and" exact="autoimmune diseases," post="and is in late-stage development as a topical ointment"/>
  <result pre="and is in late-stage development as a topical ointment for" exact="atopic dermatitis." post="Twenty trials are currently testing the efficacy of the"/>
  <result pre="a Phase 3 trial on patients with severe COVID-19 induced" exact="pneumonia" post="after promising results in the earlier phases [72]. 10.3"/>
  <result pre="the benefits are often outweighed by the risks [74] of" exact="secondary" post="infection and delayed viral clearance. 10.3.2 Dexamethasone It is"/>
  <result pre="benefits are often outweighed by the risks [74] of secondary" exact="infection" post="and delayed viral clearance. 10.3.2 Dexamethasone It is a"/>
  <result pre="outweighed by the risks [74] of secondary infection and delayed" exact="viral" post="clearance. 10.3.2 Dexamethasone It is a glucocorticoid that has"/>
  <result pre="for several years in the treatment of various inflammatory and" exact="autoimmune diseases." post="Preliminary results from the RECOVERY trial have shown that"/>
  <result pre="The drug did not improve survival in patients not requiring" exact="respiratory" post="support. Dexamethasone has been approved for use as a"/>
  <result pre="Dexamethasone suppresses the immune system and could thus potentially exacerbate" exact="viral" post="infections. However, its immunosuppressant effects might benefit COVID-19 patients"/>
  <result pre="the infected cells. Moreover, ACE2 CAR-NK cells can competitively inhibit" exact="infection" post="of ATII cells by SARS-CoV-2 through ACE2 receptors, thereby"/>
  <result pre="by SARS-CoV-2 through ACE2 receptors, thereby preventing the production of" exact="infectious" post="virus particles. A multicenter, randomized Phase 1/2 trial (NCT04324996)"/>
  <result pre="200 participants in Austria to determine if it can prevent" exact="viral" post="entry and reduce viral replication in COVID-19 patients. Results"/>
  <result pre="to determine if it can prevent viral entry and reduce" exact="viral" post="replication in COVID-19 patients. Results from the study are"/>
  <result pre="study their cardioprotective effect and prevent direct damage to the" exact="heart" post="muscle that appears to exacerbate the severity of COVID-19"/>
  <result pre="their cardioprotective effect and prevent direct damage to the heart" exact="muscle" post="that appears to exacerbate the severity of COVID-19 in"/>
  <result pre="infusion of CP is a potential therapeutic option in the" exact="absence of" post="a proven anti-viral agent or vaccine. In CP therapy,"/>
  <result pre="Convalescent plasma has previously been used in the treatment of" exact="viral" post="diseases such as poliomyelitis, influenza, SARS, and MERS. A"/>
  <result pre="clinical symptoms improved significantly within three days, and that the" exact="viral" post="load was undetectable after seven days of transfusion [78]."/>
  <result pre="Current data is still insufficient on whether mild or asymptomatic" exact="infections" post="generate adequate antibody responses or protection to COVID-19. 12"/>
  <result pre="Currently, there are no FDA-approved vaccines for COVID-19. There is" exact="limited" post="information on the specific antigens used in the development"/>
  <result pre="candidate vaccines are aimed at inducing neutralizing antibodies against the" exact="viral" post="spike (S) protein, which prevents its uptake via the"/>
  <result pre="Lipid nanoparticle encapsulated mRNA vaccine encoding S protein. Randomized; Double" exact="blind" post="Moderna/National Institute Of Allergy And Infectious Diseases (NIAID) Phase"/>
  <result pre="S protein. Randomized; Double blind Moderna/National Institute Of Allergy And" exact="Infectious" post="Diseases (NIAID) Phase II trial (NCT04405076) 600 United States"/>
  <result pre="protein. Randomized; Double blind Moderna/National Institute Of Allergy And Infectious" exact="Diseases" post="(NIAID) Phase II trial (NCT04405076) 600 United States August"/>
  <result pre="INO-4800 DNA plasmid vaccine. Non-Randomized; Open Label Inovio PharmaceuticalsANDCoalition For" exact="Epidemic" post="Preparedness Innovations (CEPI) Phase I (NCT04336410) 40 Philadelphia and"/>
  <result pre="Philadelphia and Kansas City, USA April 2021 AD5-nCov Recombinant non-replicating" exact="viral" post="vector vaccine. (adenovirus type 5 vector) Non-Randomized; Open Label"/>
  <result pre="USA April 2021 AD5-nCov Recombinant non-replicating viral vector vaccine. (adenovirus" exact="type 5" post="vector) Non-Randomized; Open Label Cansino Biological Inc./Beijing Institute of"/>
  <result pre="200 Berlin, Germany August 2020 Inactivated Vaccine Inactivated Novel Coronavirus" exact="Pneumonia" post="vaccine (Vero cells) Randomized; Double blind Wuhan Institute of"/>
  <result pre="Vaccine Inactivated Novel Coronavirus Pneumonia vaccine (Vero cells) Randomized; Double" exact="blind" post="Wuhan Institute of Biological ProductsANDChina National Pharmaceutical Group (Sinopharm)"/>
  <result pre="BBIBP-CorV Inactivated novel coronavirus (2019-CoV) vaccine (Vero cells) Randomized; Double" exact="blind" post="Beijing Institute of Biological ProductsANDChina National Pharmaceutical Group (Sinopharm)"/>
  <result pre="China November 2021 GX-19 COVID-19 Preventive DNA Vaccine Randomized; Double" exact="blind" post="Genexine Phase I/IIa (NCT04445389) 190 Seoul, Republic of Korea"/>
  <result pre="(NCT04445389) 190 Seoul, Republic of Korea March 2021 Gam-COVID-Vac Non-replicating" exact="viral" post="vector COVID-19 vaccine candidate Non-Randomized; Open Label Gamaleya Research"/>
  <result pre="CpG 1018 adjuvant with potassium aluminum sulfate (Alum) Randomized; Triple" exact="blind" post="GlaxoSmithKline,Â Sanofi,Â Clover Biopharmaceuticals, DynavaxÂ and Xiamen Innovax Phase"/>
  <result pre="Australia March 2021 COVAX-19 Monovalent recombinant protein vaccine Randomized; Triple" exact="blind" post="Vaxine Pty Ltd. Phase I (NCT04453852) 40 Adelaide, Australia"/>
  <result pre="bacTRL-Spike Bifidobacteria monovalent SARS-CoV-2 DNA oral vaccine candidate Randomized; Triple" exact="blind" post="Symvivo Phase I (NCT04334980) 112 Canada and United States"/>
  <result pre="States December 2021 Covaxin (BBV152) Inactivated whole-virion vaccine Randomized; Triple" exact="blind" post="Bharat BiotechANDNational Institute of Virology Phase I/II (NCT04471519) 1125"/>
  <result pre="to commence) 1048 India 2021 *- Repurposed Vaccine; Original indication:" exact="Tuberculosis" post="(TB) pediatric vaccine **- To-be-declared. This table gives an"/>
  <result pre="Number Title Interventions Phase Allocation &amp;amp; masking Enrollment no. (age)" exact="Primary" post="outcome measures References NCT04343768 An Investigation Into Beneficial Effects"/>
  <result pre="Interferon Î²-1b And The Base Therapeutic Regiment in Moderate to" exact="Severe" post="COVID-19: A Randomized Clinical Trial HydroxychloroquineÂ +Â Lopinavir /"/>
  <result pre="improvement [86] NCT04244591 Glucocorticoid Therapy for Critically Ill Patients With" exact="Severe" post="Acute Respiratory Infections Caused by COVID-19: a Prospective, Randomized"/>
  <result pre="[86] NCT04244591 Glucocorticoid Therapy for Critically Ill Patients With Severe" exact="Acute" post="Respiratory Infections Caused by COVID-19: a Prospective, Randomized Controlled"/>
  <result pre="NCT04244591 Glucocorticoid Therapy for Critically Ill Patients With Severe Acute" exact="Respiratory" post="Infections Caused by COVID-19: a Prospective, Randomized Controlled Trial"/>
  <result pre="Glucocorticoid Therapy for Critically Ill Patients With Severe Acute Respiratory" exact="Infections" post="Caused by COVID-19: a Prospective, Randomized Controlled Trial Experimental:"/>
  <result pre="Lower Murray lung injury score NCT04291729 Evaluation of Ganovo (Danoprevir)" exact="Combined" post="With Ritonavir in the Treatment of SARS-CoV-2 Infection Experimental:"/>
  <result pre="Ganovo (Danoprevir) Combined With Ritonavir in the Treatment of SARS-CoV-2" exact="Infection" post="Experimental: GanovoÂ +Â ritonavir with or without interferon nebulization"/>
  <result pre="30(â‰¥18) The virological clearance rate of throat swabs, sputum, or" exact="lower" post="respiratory tract secretions at day 3, 5, and 7.The"/>
  <result pre="The virological clearance rate of throat swabs, sputum, or lower" exact="respiratory" post="tract secretions at day 3, 5, and 7.The mortality"/>
  <result pre="Not Applicable Non-Randomized; Open Label 20 (18 to 80 y/o)" exact="Respiratory" post="system compliance improvement [Â TimeÂ Frame:Â 20Â minÂ ]"/>
  <result pre="Label 127(â‰¥18) Time to negative nasopharyngeal swab (NPS) 2019-n-CoV coronavirus" exact="viral" post="RT-PCR NCT04368377 Platelet Inhibition With GP IIb/IIIa Inhibitor in"/>
  <result pre="to negative nasopharyngeal swab (NPS) 2019-n-CoV coronavirus viral RT-PCR NCT04368377" exact="Platelet" post="Inhibition With GP IIb/IIIa Inhibitor in Critically Ill Patients"/>
  <result pre="With GP IIb/IIIa Inhibitor in Critically Ill Patients With Coronavirus" exact="Disease" post="2019 (COVID-19). A Compassionate Use Protocol Experimental: 25Â Âµg/kg"/>
  <result pre="48 and 168Â h after treatment initiation NCT04324489 DAS181 for" exact="Severe" post="COVID-19: Compassionate Use Experimental: DAS181 TreatmentPatient receives nebulized DAS181"/>
  <result pre="Experimental: DAS181 TreatmentPatient receives nebulized DAS181 (4.5Â mg BID/day, a" exact="total" post="9Â mg/day) for 10Â days. Not Applicable Single Group"/>
  <result pre="14Â days [Â TimeÂ Frame:Â 14Â daysÂ ] NCT04378712 Hydrogen/Oxygen" exact="Mixed" post="Gas Inhalation for Coronavirus Disease 2019 (COVID-19) Experimental: Intervention"/>
  <result pre="14Â daysÂ ] NCT04378712 Hydrogen/Oxygen Mixed Gas Inhalation for Coronavirus" exact="Disease" post="2019 (COVID-19) Experimental: Intervention Group Patients in treatment group"/>
  <result pre="90 (18 to 75 y/o) Proportion of patients with improved" exact="disease" post="severity at day 2 [Â TimeÂ Frame:Â from baseline"/>
  <result pre="from baseline to day 2Â ];Proportion of patients with improved" exact="disease" post="severity at day 3 [Â TimeÂ Frame:Â from baseline"/>
  <result pre="from baseline to day 3Â ];ANDProportion of patients with improved" exact="disease" post="severity at the day before hospital discharge [Â TimeÂ"/>
  <result pre="of Remdesivir while hospitalized for up to a 10Â days" exact="total" post="course. nÂ =Â 286.VSPlacebo Comparator: Placebo Phase 3 Randomized;"/>
  <result pre="of SARS-CoV-2Study 1 â€&quot; Contacts receive Hydroxychloroquine prophylaxis. Contacts will" exact="complete" post="a survey collecting demographic, epidemiological and clinical and provides"/>
  <result pre="Prevent Clinical Decompensation in Hospitalized, Non-critically Ill Patients With COVID-19" exact="Pneumonitis" post="(COVIDOSE) Experimental: Group A: Tocilizumab (beginning dose 200Â mg)"/>
  <result pre="Study Evaluating the Safety and Efficacy of Autologous Non-Hematopoietic Peripheral" exact="Blood" post="Stem Cells in COVID-19 (SENTAD-COVID) Experimental: Group AAutologous Non-Hematopoietic"/>
  <result pre="Stem Cells in COVID-19 (SENTAD-COVID) Experimental: Group AAutologous Non-Hematopoietic Peripheral" exact="Blood" post="Stem Cells (NHPBSC) therapy as add-on COVID-19 standard care.The"/>
  <result pre="Phase 3 Randomized; Open Label 100 (18 to 80 y/o)" exact="Viral" post="clearance [Â TimeÂ Frame:Â 14Â daysÂ ]Clinical improvement [Â"/>
  <result pre="and Safety of Liposomal Lactoferrin in COVID-19 Patients With Mild-to-Moderate" exact="Disease" post="and in COVID-19 Asymptomatic Patients Experimental: Group 1a (COVID-19"/>
  <result pre="5 capsules in the evening for 30Â days for a" exact="total" post="of 1Â g of lactoferrin / day; patients with"/>
  <result pre="into 3 administrations / day for 30Â days for a" exact="total" post="of 1.5Â g of lactoferrin per day; intra-nasal spray:"/>
  <result pre="to carefully clean the nasal cavity.VSNo Intervention: Group 1b15 mild-to-moderate" exact="symptomatic" post="patients in hospitalization regimen were enrolled in the control"/>
  <result pre="group (2a) Phase 2/3 Randomized; Open Label 60(â‰¥20) Rate of" exact="viral" post="clearance Time to viral clearance [Â TimeÂ Frame:Â 30Â"/>
  <result pre="Randomized; Open Label 60(â‰¥20) Rate of viral clearance Time to" exact="viral" post="clearance [Â TimeÂ Frame:Â 30Â daysÂ ] time to"/>
  <result pre="naso-oro-pharingeal swab negativization NCT04345276 Efficacy and Safety of Ganovo (Danoprevir)" exact="Combined" post="With Ritonavir in the Treatment of SARS-CoV-2 Infection Experimental:"/>
  <result pre="Ganovo (Danoprevir) Combined With Ritonavir in the Treatment of SARS-CoV-2" exact="Infection" post="Experimental: DanoprevirÂ +Â Ritonavir groupDanoprevir 100Â mg, one tablet"/>
  <result pre="93% without oxygen supplementation, PaO2/FiO2Â â‰¤Â 300Â mmHg or a" exact="respiratory" post="rateÂ â‰¥Â 30 breaths per min without supplemental oxygen"/>
  <result pre="mg/dailyÂ +Â azithromycin 500Â mg daily Phase 1 Randomized; Double" exact="blind" post="100(â‰¥18) Number of cured patients [Â TimeÂ Frame:Â 4Â"/>
  <result pre="Frame:Â day 1, 4, 7, 14 after first transfusionÂ ]C-Reactive" exact="Protein" post="(CRP) [Â TimeÂ Frame:Â day 1, 4, 7, 14"/>
  <result pre="NCT04342650 Chloroquine Diphosphate in the Prevention of SARS in Covid-19" exact="Infection" post="(CloroCOVID19II) Active Comparator: InterventionCQ 450Â mg twice daily (3"/>
  <result pre="to D5. Oral administration.VSPlacebo Comparator: Placebo Phase 2 Randomized; Quadruple" exact="blind" post="152(â‰¥18) Proportion of patients with onset of severe acute"/>
  <result pre="Quadruple blind 152(â‰¥18) Proportion of patients with onset of severe" exact="acute" post="respiratory syndrome (SARS) [Â TimeÂ Frame:Â 7Â days after"/>
  <result pre="blind 152(â‰¥18) Proportion of patients with onset of severe acute" exact="respiratory" post="syndrome (SARS) [Â TimeÂ Frame:Â 7Â days after randomizationÂ"/>
  <result pre="152(â‰¥18) Proportion of patients with onset of severe acute respiratory" exact="syndrome" post="(SARS) [Â TimeÂ Frame:Â 7Â days after randomizationÂ ]"/>
  <result pre="after randomizationÂ ] NCT04323527 Chloroquine Diphosphate for the Treatment of" exact="Severe" post="Acute Respiratory Syndrome Secondary to SARS-CoV2 (CloroCOVID19) Active Comparator:"/>
  <result pre="randomizationÂ ] NCT04323527 Chloroquine Diphosphate for the Treatment of Severe" exact="Acute" post="Respiratory Syndrome Secondary to SARS-CoV2 (CloroCOVID19) Active Comparator: Low"/>
  <result pre="] NCT04323527 Chloroquine Diphosphate for the Treatment of Severe Acute" exact="Respiratory" post="Syndrome Secondary to SARS-CoV2 (CloroCOVID19) Active Comparator: Low Dose"/>
  <result pre="NCT04323527 Chloroquine Diphosphate for the Treatment of Severe Acute Respiratory" exact="Syndrome" post="Secondary to SARS-CoV2 (CloroCOVID19) Active Comparator: Low Dose Chloroquine"/>
  <result pre="Chloroquine Diphosphate for the Treatment of Severe Acute Respiratory Syndrome" exact="Secondary" post="to SARS-CoV2 (CloroCOVID19) Active Comparator: Low Dose Chloroquine Diphosphate"/>
  <result pre="nasogastric tube in case of orotracheal intubation. Phase 2 Randomized;Quadruple" exact="blind" post="278(â‰¥18) Mortality rate reduction of 50% by day 28"/>
  <result pre="Therapy GroupStandart critical care treatment group Not Applicable Randomized; Double" exact="blind" post="60(18 to 90 y/o) Plasma ferritin level [Â TimeÂ"/>
  <result pre="for 4 consecutive daysVSPlacebo Comparator: Placebo Phase 3 Randomized; Quadruple" exact="blind" post="1309(â‰¥18) Incidence of COVID19 Disease among those who are"/>
  <result pre="Placebo Phase 3 Randomized; Quadruple blind 1309(â‰¥18) Incidence of COVID19" exact="Disease" post="among those who are asymptomatic at baseline [Â TimeÂ"/>
  <result pre="baseline [Â TimeÂ Frame:Â 14Â daysÂ ] Overall change in" exact="disease" post="severity over 14Â days among those who are symptomatic"/>
  <result pre="in disease severity over 14Â days among those who are" exact="symptomatic" post="at baseline [Â TimeÂ Frame:Â 14Â daysÂ ] NCT04444986"/>
  <result pre="impact of COVID-19, vigilant follow-up of those recovering from the" exact="disease" post="is needed. Previous respiratory diseases brought about by coronaviruses"/>
  <result pre="follow-up of those recovering from the disease is needed. Previous" exact="respiratory" post="diseases brought about by coronaviruses have resulted in deranged"/>
  <result pre="resulted in deranged lipid and glucose metabolism as well as" exact="cardiovascular" post="issues in recovered individuals for up to 12Â years"/>
  <result pre="antibodies is key to developing a broader understanding of the" exact="disease" post="dynamics of COVID-19. It will also shed light on"/>
  <result pre="near future. New diagnostic modalities, serological tests, contact-tracing technologies and" exact="disease" post="surveillance tools are essential to reduce the impact of"/>
  <result pre="be generalizable to the pediatric population. Second, the search was" exact="limited" post="to only English-language articles which might have been a"/>
  <result pre="pneumoniaN. Engl. J. Med.38220201199120731995857 4ZhuN.A novel coronavirus from patients with" exact="pneumonia" post="in China, 2019N. Engl. J. Med.382202072773331978945 5A.E. Gorbalenya, et"/>
  <result pre="in China, 2019N. Engl. J. Med.382202072773331978945 5A.E. Gorbalenya, et al.," exact="Severe" post="acute respiratory syndrome-related coronavirus: The species and its viruses"/>
  <result pre="China, 2019N. Engl. J. Med.382202072773331978945 5A.E. Gorbalenya, et al., Severe" exact="acute" post="respiratory syndrome-related coronavirus: The species and its viruses â€&quot;"/>
  <result pre="2019N. Engl. J. Med.382202072773331978945 5A.E. Gorbalenya, et al., Severe acute" exact="respiratory" post="syndrome-related coronavirus: The species and its viruses â€&quot; a"/>
  <result pre="July 2003 https://www.who.int/csr/sars/country/table2004_04_21/en/. (2020). Accessed 25 April 2020. 10Middle East" exact="respiratory" post="syndrome coronavirus (MERS-CoV) https://www.who.int/emergencies/mers-cov/en/. (2020). Accessed 25 April 2020."/>
  <result pre="2003 https://www.who.int/csr/sars/country/table2004_04_21/en/. (2020). Accessed 25 April 2020. 10Middle East respiratory" exact="syndrome" post="coronavirus (MERS-CoV) https://www.who.int/emergencies/mers-cov/en/. (2020). Accessed 25 April 2020. 11van"/>
  <result pre="crisis of national developmentNat. Hum. Behav.202010.1038/s41562-020-0852-7 12Chan-YeungM.XuR.-H.SARS: epidemiologyRespirology82003S9S1415018127 13KillerbyM.E.BiggsH.M.MidgleyC.M.GerberS.I.WatsonJ.T.Middle east" exact="respiratory" post="syndrome coronavirus transmissionEmerg. Infect. Dis.26202019119831961300 14ZhouP.A pneumonia outbreak associated"/>
  <result pre="of national developmentNat. Hum. Behav.202010.1038/s41562-020-0852-7 12Chan-YeungM.XuR.-H.SARS: epidemiologyRespirology82003S9S1415018127 13KillerbyM.E.BiggsH.M.MidgleyC.M.GerberS.I.WatsonJ.T.Middle east respiratory" exact="syndrome" post="coronavirus transmissionEmerg. Infect. Dis.26202019119831961300 14ZhouP.A pneumonia outbreak associated with"/>
  <result pre="epidemiologyRespirology82003S9S1415018127 13KillerbyM.E.BiggsH.M.MidgleyC.M.GerberS.I.WatsonJ.T.Middle east respiratory syndrome coronavirus transmissionEmerg. Infect. Dis.26202019119831961300 14ZhouP.A" exact="pneumonia" post="outbreak associated with a new coronavirus of probable bat"/>
  <result pre="(2020). Accessed 24 April 2020. 20Chinese Clinical Guidance for COVID-19" exact="Pneumonia" post="Diagnosis and Treatment, 7th ed. http://kjfy.meetingchina.org/msite/news/show/cn/3337.html. (2020). Accessed 25"/>
  <result pre="Sci. (2020). doi:10.20944/preprints202004.0091.v1. 27SancheS.LinY.T.XuC.Romero-SeversonE.HengartnerN.KeR.High contagiousness and rapid spread of severe" exact="acute" post="respiratory syndrome coronavirus 2Emerg. Infect. Dis.2020Jul 202010.3201/eid2607.200282 28Therapeutic Options"/>
  <result pre="(2020). doi:10.20944/preprints202004.0091.v1. 27SancheS.LinY.T.XuC.Romero-SeversonE.HengartnerN.KeR.High contagiousness and rapid spread of severe acute" exact="respiratory" post="syndrome coronavirus 2Emerg. Infect. Dis.2020Jul 202010.3201/eid2607.200282 28Therapeutic Options for"/>
  <result pre="doi:10.20944/preprints202004.0091.v1. 27SancheS.LinY.T.XuC.Romero-SeversonE.HengartnerN.KeR.High contagiousness and rapid spread of severe acute respiratory" exact="syndrome" post="coronavirus 2Emerg. Infect. Dis.2020Jul 202010.3201/eid2607.200282 28Therapeutic Options for COVID-19"/>
  <result pre="Xiong, S. Redwood, B. Prendergast, M. Chen, Coronaviruses and the" exact="cardiovascular" post="system: acute and long-term implications. Eur. Heart J. ehaa231"/>
  <result pre="Redwood, B. Prendergast, M. Chen, Coronaviruses and the cardiovascular system:" exact="acute" post="and long-term implications. Eur. Heart J. ehaa231 (2020). doi:10.1093/eurheartj/ehaa231."/>
  <result pre="Coronaviruses and the cardiovascular system: acute and long-term implications. Eur." exact="Heart" post="J. ehaa231 (2020). doi:10.1093/eurheartj/ehaa231. 31LiB.Prevalence and impact of cardiovascular"/>
  <result pre="Eur. Heart J. ehaa231 (2020). doi:10.1093/eurheartj/ehaa231. 31LiB.Prevalence and impact of" exact="cardiovascular" post="metabolic diseases on COVID-19 in ChinaClin. Res. Cardiol.109202053153832161990 32C."/>
  <result pre="Heart J. ehaa231 (2020). doi:10.1093/eurheartj/ehaa231. 31LiB.Prevalence and impact of cardiovascular" exact="metabolic diseases" post="on COVID-19 in ChinaClin. Res. Cardiol.109202053153832161990 32C. Fan, K."/>
  <result pre="Urology (2020). doi:10.1101/2020.02.12.20022418. 33MorenoL.PearsonA.D.How can attrition rates be reduced in" exact="cancer" post="drug discovery?Expert Opin. Drug Discov.8201336336823373702 34WangM.Remdesivir and chloroquine effectively"/>
  <result pre="the COVID-19Travel Med. Infect. Dis.101615202010.1016/j.tmaid.2020.101615 36M.L. Agostini, et al., Coronavirus" exact="susceptibility to" post="the antiviral remdesivir (GS-5734) is mediated by the viral"/>
  <result pre="susceptibility to the antiviral remdesivir (GS-5734) is mediated by the" exact="viral" post="polymerase and the proofreading exoribonuclease, mBio 9 (2018) e00221â€&quot;18."/>
  <result pre="Grein, et al., Compassionate Use of Remdesivir for Patients with" exact="Severe" post="Covid-19, N. Engl. J. Med. NEJMoa2007016 (2020). doi:10.1056/NEJMoa2007016. 38WangY.Remdesivir"/>
  <result pre="July 2020. 44ShamH.L.ABT-378, a highly potent inhibitor of the human" exact="immunodeficiency" post="virus proteaseAntimicrob. Agents Chemother.421998321832249835517 45ChuC.M.Role of lopinavir/ritonavir in the"/>
  <result pre="FDA-approved compound library identifies four small-molecule inhibitors of middle east" exact="respiratory" post="syndrome coronavirus replication in cell cultureAntimicrob. Agents Chemother.5820144875488424841269 47B."/>
  <result pre="compound library identifies four small-molecule inhibitors of middle east respiratory" exact="syndrome" post="coronavirus replication in cell cultureAntimicrob. Agents Chemother.5820144875488424841269 47B. Cao,"/>
  <result pre="COVID-19, https://www.who.int/news-room/detail/04-07-2020-who-discontinues-hydroxychloroquine-and-lopinavir-ritonavir-treatment-arms-for-covid-19. Accessed 19 July 2020. 50TanE.L.C.Inhibition of SARS coronavirus" exact="infection" post="in vitro with clinically approved antiviral drugsEmerg. Infect. Dis.10200458158615200845"/>
  <result pre="silico assessment, in vitro and retrospective study, Infect. Diseases, except" exact="HIV/AIDS" post="(2020). doi:10.1101/2020.05.15.20102392. 52L. Dong, S. Hu, J. Gao, Discovering"/>
  <result pre="Dong, S. Hu, J. Gao, Discovering drugs to treat coronavirus" exact="disease" post="2019 (COVID-19), 3 (2020). 53FurutaY.KomenoT.NakamuraT.Favipiravir (T-705), a broad spectrum"/>
  <result pre="(COVID-19), 3 (2020). 53FurutaY.KomenoT.NakamuraT.Favipiravir (T-705), a broad spectrum inhibitor of" exact="viral" post="RNA polymeraseProc. Japan Acad. Ser. B: Phys. Biol. Sci.932017449463"/>
  <result pre="optimized dosing design of hydroxychloroquine for the treatment of severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2)Clin. Infect. Dis.202010.1093/cid/ciaa237 60GautretP.Hydroxychloroquine and"/>
  <result pre="dosing design of hydroxychloroquine for the treatment of severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2)Clin. Infect. Dis.202010.1093/cid/ciaa237 60GautretP.Hydroxychloroquine and azithromycin"/>
  <result pre="design of hydroxychloroquine for the treatment of severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2)Clin. Infect. Dis.202010.1093/cid/ciaa237 60GautretP.Hydroxychloroquine and azithromycin as"/>
  <result pre="different dosages as adjunctive therapy of hospitalized patients with severe" exact="respiratory" post="syndrome in the context of coronavirus (SARS-CoV-2) infection: preliminary"/>
  <result pre="dosages as adjunctive therapy of hospitalized patients with severe respiratory" exact="syndrome" post="in the context of coronavirus (SARS-CoV-2) infection: preliminary safety"/>
  <result pre="a randomized, double-blinded, phase IIb clinical trial (CloroCovid-19 Study), Infect." exact="Diseases" post="(except HIV/AIDS), (2020). doi:10.1101/2020.04.07.20056424. 62MehraM.R.DesaiS.S.RuschitzkaF.PatelA.N.Hydroxychloroquine or chloroquine with or"/>
  <result pre="hospital setting or a clinical trial due to risk of" exact="heart" post="rhythm problems, https://www.fda.gov/drugs/drug-safety-and-availability/fda-cautions-against-use-hydroxychloroquine-or-chloroquine-covid-19-outside-hospital-setting-or. Accessed 18 July 2020. 67ZhouF.Clinical course"/>
  <result pre="July 2020. 67ZhouF.Clinical course and risk factors for mortality of" exact="adult" post="inpatients with COVID-19 in Wuhan, China: a retrospective cohort"/>
  <result pre="China: a retrospective cohort studyLancet39520201054106232171076 68PriceC.C.Tocilizumab treatment for cytokine release" exact="syndrome" post="in hospitalized COVID-19 patientsChestS0012369220316706202010.1016/j.chest.2020.06.006 69E.C. Somers, et al., Tocilizumab"/>
  <result pre="Announces Decision to Enter Phase III Development of IFX-1 in" exact="Severe" post="COVID-19 Induced Pneumonia, https://www.globenewswire.com/news-release/2020/07/21/2064803/0/en/InflaRx-Announces-Decision-to-Enter-Phase-III-Development-of-IFX-1-in-Severe-COVID-19-Induced-Pneumonia.html. Accessed 21 July 2020. 73StockmanL.J.BellamyR.GarnerP.SARS:"/>
  <result pre="of dexamethasone in hospitalized patients with COVID-19: preliminary report, Infect." exact="Diseases" post="(except HIV/AIDS), (2020). doi:10.1101/2020.06.22.20137273. 76World first coronavirus treatment approved"/>
 </snippets>
</snippetsTree>
